SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC.
Tempus AI, Inc. Class A Common Stock
TEM
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Last trade$63.49
Day change-$1.27 (-1.96%)
Day range$61.86 – $68.75
Volume4,078,832
Market cap$11.81B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.81B
Price / earnings
—
Price / book
23.61×
Price / sales
7.83×
EV / sales
8.33×
EV / EBITDA
-72.42×
Profitability
Earnings per share
-$1.04
Return on assets
-7.72%
Return on equity
-37.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.7×
Current ratio
2.61×
Quick ratio
2.48×
Cash ratio
1.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$136.79M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TEM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$411.54M
$382.49M
$348.12M
$367.21M
$334.21M
$314.64M
$255.74M
$200.68M
Cost of revenue
$144.84M
$135.99M
$126.08M
$129.5M
$124.26M
$119.6M
$100.53M
$78.62M
Gross profit
$266.7M
$246.5M
$222.04M
$237.71M
$209.94M
$195.04M
$155.2M
$122.06M
Selling, general and administrative
$231.86M
$225.85M
$212.59M
$208.51M
$187.89M
$180.71M
$154.63M
$111.29M
Research and development
$91.71M
$52.64M
$94.16M
$50.47M
$83.05M
$41.62M
$69.27M
$29.61M
Total operating expenses
$323.57M
$322.41M
$306.75M
$299.13M
$270.94M
$256.81M
$223.89M
$172.76M
Operating income
-$56.86M
-$75.91M
-$84.71M
-$61.41M
-$61M
-$61.77M
-$68.69M
-$50.7M
Interest expense
-$6.7M
-$10.28M
-$14.34M
-$15.29M
-$15.4M
-$21.58M
-$18M
-$13.36M
Income before taxes
-$12.45M
$5.95M
-$122.9M
-$57.01M
-$81.22M
-$42.63M
-$112.33M
-$10.36M
Income taxes
$35K
$309K
-$62K
-$5.99M
$276K
$212K
-$46.18M
$122K
Net income
-$14.85M
$5.64M
-$125.92M
-$54.17M
-$79.98M
-$42.84M
-$68.04M
-$13.01M
Net income attributable to common shareholders
-$14.85M
$5.64M
-$125.92M
-$54.17M
-$79.98M
-$42.84M
-$68.04M
-$13.01M
EBITDA
-$30.63M
-$49.93M
-$58.54M
-$34.51M
-$33.97M
-$33.74M
-$48.34M
-$40.03M
Basic earnings per share
-$0.08
$0.03
-$0.70
-$0.30
-$0.46
-$0.25
-$0.40
-$0.08
Diluted earnings per share
-$0.08
$0.03
-$0.71
-$0.30
-$0.46
-$0.25
-$0.40
-$0.08
Recent news
Company coverage with links to the original publishers.
Three major healthcare companies—Illumina, Tempus AI, and Novartis—raised their FY26 guidance following positive Q3 earnings results. Illumina reported 4.2% YoY revenue growth driven by strong clinical demand and NovaSeq X placements. Tempus AI delivered record revenue with 23% YoY growth, particularly strong in its Data & Applications segment. Novartis improved its profitability outlook despite generic competition pressures.
Tempus AI reported Q3 2026 revenue of $411.54 million, slightly beating consensus estimates with a 23.1% year-over-year increase. The company posted EPS of $0.07 versus expectations of -$0.09, representing a significant 177.78% positive surprise. Diagnostics revenue grew 20% YoY while Data and applications revenue increased 32.9% YoY. However, the stock has underperformed the broader market, declining 5.8% over the past month.
Tempus AI (TEM) reported quarterly earnings of $0.07 per share, beating consensus estimates of a loss of $0.09, representing a 177.78% earnings surprise. The company posted revenues of $411.54 million, surpassing estimates by 0.05% and showing year-over-year growth from $334.21 million. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 36% of Zacks industries.
Tempus AI (TEM) appears more favorable than Doximity (DOCS) in the medical information systems sector. TEM is expected to deliver 23.1% Q3 revenue growth driven by oncology testing and data licensing, while trading at a lower valuation (7.32X P/S vs 8.53X P/S). DOCS faces headwinds from cautious pharma spending and margin pressure, with only 1.3% expected revenue growth and a 24.4% EPS decline, despite strong physician engagement and AI adoption.
Tempus AI is expected to report Q3 2026 earnings on November 2 with a consensus loss of $0.09 per share and revenues of $411.7 million (up 23.2% YoY). The company has a positive Earnings ESP of +20.00% combined with a Zacks Rank #3, suggesting a likely earnings beat. Tempus has beaten consensus EPS estimates in 3 of the last 4 quarters, including a +69.23% surprise in the most recent quarter.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 18, 2006
$0.2575
Jul 28, 2006
recurring
Jul 18, 2006
$0.4396
Jul 28, 2006
unknown
Jun 10, 2005
$0.233
Jun 22, 2005
unknown
Jun 21, 2004
$0.2201
Jun 28, 2004
unknown
Jun 16, 2003
$0.2017
Jun 26, 2003
unknown
Stock splits
Historical share-structure events and their execution dates.